By Fineline Cube 
Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB all assets related to CAN10, an IL-1RAP-targeting monoclonal antibody (mAb) under development for the treatment of autoimmune diseases. This strategic move expands Otsuka’s portfolio in autoimmune disease therapies.
Acquisition Details
Otsuka gains global exclusive rights for the development, manufacturing, and commercialization of CAN10 and related assets. Financial terms include an upfront payment of USD 33 million to Cantargia, with additional milestone payments committed as the development progresses.-Fineline Info & Tech